{"id":1983,"date":"2025-05-14T01:13:00","date_gmt":"2025-05-14T05:13:00","guid":{"rendered":"https:\/\/9bio.ca\/?p=1983"},"modified":"2026-01-20T09:25:24","modified_gmt":"2026-01-20T14:25:24","slug":"1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation","status":"publish","type":"post","link":"https:\/\/9biotx.com\/fr\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","title":{"rendered":"Une collaboration appuy\u00e9e par le Qu\u00e9bec \u00e0 hauteur de 1,8 M$ entre 9Bio et Vega fait progresser l\u2019innovation en oncologie de pr\u00e9cision"},"content":{"rendered":"

Montr\u00e9al et Qu\u00e9bec, QC, le 14 mai 2025<\/strong> \u2013 9Bio Th\u00e9rapeutiques, une entreprise de biotechnologie sp\u00e9cialis\u00e9e dans les th\u00e9rapies oncologiques de nouvelle g\u00e9n\u00e9ration, et Vega BioImagerie, une startup sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de diagnostics compagnons innovants pour les traitements oncologiques, annoncent avec fiert\u00e9 une initiative collaborative de 1,8 million de dollars en oncologie cibl\u00e9e. Le projet b\u00e9n\u00e9ficie d\u2019un soutien important du gouvernement du Qu\u00e9bec, sous la forme d\u2019une subvention de 0,9 million de dollars octroy\u00e9e dans le cadre du programme Partenar-IA du CQDM, en partenariat avec IVADO.<\/p>\n\n\n\n

Cette initiative repose sur la compl\u00e9mentarit\u00e9 des forces des deux entreprises afin d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement d\u2019un diagnostic compagnon et d\u2019un candidat th\u00e9rapeutique en oncologie, avec un premier focus sur les cancers de la t\u00eate et du cou ainsi que les cancers du sein m\u00e9tastatiques \u2013 pour lesquels de nombreux patients n\u2019ont toujours pas acc\u00e8s \u00e0 des options de traitement efficaces.<\/p>\n\n\n\n

9Bio Th\u00e9rapeutiques \u00e9largit son pipeline avec un second programme qui tire parti de sa plateforme d\u2019ing\u00e9nierie pour concevoir un conjugu\u00e9 anticorps-m\u00e9dicament (ADC) activ\u00e9 de mani\u00e8re conditionnelle. Cet ADC novateur mise sur une th\u00e9rapie oncologique d\u00e9j\u00e0 valid\u00e9e en clinique mais abandonn\u00e9e en raison d\u2019une toxicit\u00e9 \u00ab on-target, off-tumor \u00bb. Con\u00e7u pour \u00e9liminer les cellules tumorales r\u00e9sistantes \u00e0 la chimioth\u00e9rapie, il vise \u00e0 surmonter les limitations de s\u00e9curit\u00e9 observ\u00e9es tout en conservant l\u2019efficacit\u00e9 prometteuse d\u00e9montr\u00e9e dans trois essais cliniques de phase 1 chez l\u2019humain.<\/p>\n\n\n\n

Vega BioImagerie vient compl\u00e9ter cette approche avec une plateforme diagnostique avanc\u00e9e combinant nanotechnologie, optique haute r\u00e9solution et analyses bas\u00e9es sur l\u2019IA afin de permettre une d\u00e9tection pr\u00e9cise des biomarqueurs. La technologie de Vega vise \u00e0 corriger le taux \u00e9lev\u00e9 d\u2019erreurs dans les diagnostics compagnons \u2013 variant de 7 % \u00e0 30 % selon la pathologie \u2013 caus\u00e9 par un manque de quantification. Ces erreurs entra\u00eenent souvent des prescriptions sous-optimales, que la plateforme cherche \u00e0 \u00e9viter en am\u00e9liorant la s\u00e9lection des patients pour les essais cliniques et les d\u00e9cisions th\u00e9rapeutiques. Vega soutiendra 9Bio en d\u00e9veloppant un kit de diagnostic compagnon personnalis\u00e9, con\u00e7u pour \u00e9valuer les crit\u00e8res d'inclusion des patients et pr\u00e9dire avec pr\u00e9cision la r\u00e9ponse au traitement. Cela permettra d\u2019am\u00e9liorer la stratification des patients et augmentera consid\u00e9rablement les chances de r\u00e9ussite des essais cliniques.<\/p>\n\n\n\n

\u00ab Chez 9Bio, notre objectif a toujours \u00e9t\u00e9 de d\u00e9velopper des traitements s\u00fbrs et efficaces qui r\u00e9pondent aux besoins r\u00e9els des patients atteints de cancer \u00bb, d\u00e9clare Philipe Gobeil, cofondateur de 9Bio Th\u00e9rapeutiques. \u00ab Ce partenariat nous permet de renforcer cette mission gr\u00e2ce \u00e0 une collaboration compl\u00e9mentaire avec une entreprise remarquable comme Vega, soutenue par des organismes qui reconnaissent l\u2019urgence d\u2019innover en oncologie. \u00bb<\/p>\n\n\n\n

\u00ab Notre collaboration avec 9Bio nous permet de valider nos outils de diagnostic compagnon dans un contexte r\u00e9el de d\u00e9veloppement th\u00e9rapeutique, d\u00e9montrant davantage la valeur clinique et l\u2019impact de notre plateforme \u00bb, affirme C\u00e9cile Darviot, PDG de Vega BioImagerie.<\/p>\n\n\n\n

Bien que cette collaboration repose sur une expertise synergique, chaque entreprise conservera l\u2019int\u00e9gralit\u00e9 de sa propri\u00e9t\u00e9 intellectuelle, assurant un \u00e9quilibre entre d\u00e9veloppement collaboratif et cr\u00e9ation de valeur ind\u00e9pendante tout en faisant progresser des solutions innovantes en oncologie.<\/p>\n\n\n\n

Ce projet repr\u00e9sente une avanc\u00e9e significative vers une innovation plus efficace en oncologie, avec le potentiel d\u2019am\u00e9liorer les chances de survie et la qualit\u00e9 de vie des patients atteints de cancers agressifs et difficiles \u00e0 traiter. En r\u00e9unissant des entreprises issues de diff\u00e9rentes r\u00e9gions de la province et en mettant en commun le meilleur de leurs technologies, cette initiative met en lumi\u00e8re la force des collaborations au Qu\u00e9bec et positionne la province \u00e0 l\u2019avant-garde mondiale des sciences de la vie.<\/p>\n\n\n\n

\u00ab Le Qu\u00e9bec se distingue comme un terreau fertile pour la recherche et l\u2019innovation, port\u00e9 par un \u00e9cosyst\u00e8me unique qui accompagne les entreprises \u00e0 chaque \u00e9tape de leur croissance. Nous sommes fiers de soutenir ce projet qui mise sur les avanc\u00e9es de l\u2019intelligence artificielle pour transformer les options th\u00e9rapeutiques et les outils diagnostiques destin\u00e9s aux personnes atteintes de cancer, avec des retomb\u00e9es concr\u00e8tes pour leur qualit\u00e9 de vie et pour l\u2019\u00e9conomie locale. \u00bb affirme V\u00e9ronique Dugas, pr\u00e9sidente et directrice g\u00e9n\u00e9rale du CQDM.<\/p>\n\n\n\n

\u00ab IVADO est fier de soutenir une initiative qui met l\u2019intelligence artificielle au service de la sant\u00e9 de demain. En combinant mod\u00e9lisation avanc\u00e9e des prot\u00e9ines et m\u00e9decine de pr\u00e9cision, ce projet ouvre la voie \u00e0 des traitements plus cibl\u00e9s et mieux tol\u00e9r\u00e9s, avec un impact concret sur la qualit\u00e9 de vie des personnes atteintes de cancers complexes. \u00bb, compl\u00e8te Nancy Laram\u00e9e, directrice des partenariats d\u2019IVADO.<\/p>\n\n\n\n

Lisez le communiqu\u00e9 officiel du CQDM ici<\/a>.<\/p>\n\n\n\n

\n\n\n\n

\u00c0 propos de 9Bio Th\u00e9rapeutiques<\/strong><\/p>\n\n\n\n

9Bio est une entreprise de biotechnologie d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies oncologiques innovantes. Notre plateforme de biologie structurale guid\u00e9e par l'IA int\u00e8gre des contextes anatomiques et biochimiques pour concevoir des m\u00e9dicaments ciblant s\u00e9lectivement les tumeurs. Gr\u00e2ce \u00e0 cette approche, nous d\u00e9veloppons des traitements sp\u00e9cifiquement dirig\u00e9s contre les tumeurs, tout en pr\u00e9servant les tissus sains, am\u00e9liorant ainsi la s\u00e9curit\u00e9, l\u2019efficacit\u00e9 et ouvrant la voie \u00e0 des modalit\u00e9s th\u00e9rapeutiques jusqu\u2019ici sous-exploit\u00e9es. Notre pipeline comprend deux th\u00e9rapies en phase de d\u00e9couverte : un conjugu\u00e9 anticorps-m\u00e9dicament (ADC) ciblant les cellules tumorales chimior\u00e9sistantes et un autre ADC ciblant les cellules immunitaires subverties par les tumeurs.<\/p>\n\n\n\n

\u00c0 propos de Vega BioImagerie<\/strong><\/p>\n\n\n\n

Vega BioImaging r\u00e9volutionne le diagnostic du cancer gr\u00e2ce \u00e0 la premi\u00e8re plateforme d'imagerie quantitative multiprot\u00e9ique, alliant nanotechnologie et intelligence artificielle. Sa technologie brevet\u00e9e permet de d\u00e9tecter de multiples biomarqueurs avec une sensibilit\u00e9 in\u00e9gal\u00e9e, tant dans les \u00e9chantillons tissulaires que cytologiques, tout en s'int\u00e9grant parfaitement aux flux de travail pathologiques existants. R\u00e9sultat : des diagnostics plus fiables, une meilleure stratification des patients et moins d'\u00e9checs dans les essais cliniques. Pour en savoir plus, rendez-vous sur https:\/\/www.vegabioimaging.com\/fr\/accueil\/<\/a>.<\/p>\n\n\n\n

\u00c0 propos du CQDM<\/strong><\/p>\n\n\n\n

Facilitateur d\u2019innovation biopharma<\/em><\/p>\n\n\n\n

Le CQDM est un consortium de recherche biopharmaceutique \u00e0 but non lucratif dont la mission est de soutenir et de faciliter la recherche et d\u00e9veloppement collaborative multipartite visant \u00e0 acc\u00e9l\u00e9rer la translation ou la transformation de technologies innovantes en solutions r\u00e9pondant \u00e0 des besoins m\u00e9dicaux non satisfaits, tout en g\u00e9n\u00e9rant des retomb\u00e9es significatives pour l\u2019\u00e9conomie qu\u00e9b\u00e9coise et canadienne. Pour plus d\u2019informations, consultez le site web https:\/\/www.cqdm.org<\/a> et rejoignez-nous sur Twitter\/X @CQDM_Canada and LinkedIn.<\/p>\n\n\n\n

Partenar-IA<\/strong> est un programme de soutien direct aux entreprises qu\u00e9b\u00e9coises pour la r\u00e9alisation de projets de R-D biopharmaceutique collaborative fond\u00e9s sur l\u2019intelligence artificielle et applicables au secteur biopharmaceutique.<\/p>\n\n\n\n

\u00c0 propos d\u2019IVADO<\/strong><\/p>\n\n\n\n

IVADO est un consortium interdisciplinaire et intersectoriel de recherche, de formation et de mobilisation des connaissances qui a pour mission de b\u00e2tir et de promouvoir une intelligence artificielle robuste, raisonnante et responsable. Pilot\u00e9 par l\u2019Universit\u00e9 de Montr\u00e9al, avec 4 partenaires universitaires (Polytechnique Montr\u00e9al, HEC Montr\u00e9al, Universit\u00e9 Laval et Universit\u00e9 McGill), IVADO rassemble des centres de recherches, des partenaires gouvernementaux et industriels, pour coconstruire des initiatives intersectorielles ambitieuses favorisant un changement de paradigme de l\u2019IA et de son adoption. Pour plus d\u2019informations, consultez le site web https:\/\/ivado.ca\/<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

9Bio Th\u00e9rapeutiques et Vega BioImagerie, une startup sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de diagnostics compagnons innovants pour les traitements oncologiques, annoncent avec fiert\u00e9 une initiative collaborative de 1,8 million de dollars en oncologie cibl\u00e9e. Le projet b\u00e9n\u00e9ficie d\u2019un soutien important du gouvernement du Qu\u00e9bec, sous la forme d\u2019une subvention de 0,9 million de dollars octroy\u00e9e dans le cadre du programme Partenar-IA du CQDM, en partenariat avec IVADO.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-1983","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"\n$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation - 9Bio Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/9biotx.com\/fr\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation - 9Bio Therapeutics\" \/>\n<meta property=\"og:description\" content=\"9Bio Therapeutics and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are pleased to announce a collaborative $1.8 million initiative in targeted oncology therapies. The project has received significant support from the Government of Quebec, in the form of a $0.9 million grant through CQDM\u2019s Partenar-IA program, in partnership with IVADO.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/9biotx.com\/fr\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"9Bio Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T05:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T14:25:24+00:00\" \/>\n<meta name=\"author\" content=\"Henrique de Carvalho\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrique de Carvalho\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\"},\"author\":{\"name\":\"Henrique de Carvalho\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\"},\"headline\":\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation\",\"datePublished\":\"2025-05-14T05:13:00+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\"},\"wordCount\":947,\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\",\"name\":\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation - 9Bio Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\"},\"datePublished\":\"2025-05-14T05:13:00+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/9biotx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"name\":\"9Bio Therapeutics\",\"description\":\"Engineering Biological Possibilities\",\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/9biotx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\",\"name\":\"9Bio Therapeutics\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"contentUrl\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"width\":200,\"height\":80,\"caption\":\"9Bio Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/9bio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\",\"name\":\"Henrique de Carvalho\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"caption\":\"Henrique de Carvalho\"},\"sameAs\":[\"https:\\\/\\\/9bio.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation - 9Bio Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/9biotx.com\/fr\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","og_locale":"fr_CA","og_type":"article","og_title":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation - 9Bio Therapeutics","og_description":"9Bio Therapeutics and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are pleased to announce a collaborative $1.8 million initiative in targeted oncology therapies. The project has received significant support from the Government of Quebec, in the form of a $0.9 million grant through CQDM\u2019s Partenar-IA program, in partnership with IVADO.","og_url":"https:\/\/9biotx.com\/fr\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","og_site_name":"9Bio Therapeutics","article_published_time":"2025-05-14T05:13:00+00:00","article_modified_time":"2026-01-20T14:25:24+00:00","author":"Henrique de Carvalho","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Henrique de Carvalho","Estimation du temps de lecture":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#article","isPartOf":{"@id":"https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/"},"author":{"name":"Henrique de Carvalho","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8"},"headline":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation","datePublished":"2025-05-14T05:13:00+00:00","dateModified":"2026-01-20T14:25:24+00:00","mainEntityOfPage":{"@id":"https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/"},"wordCount":947,"publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"articleSection":["News"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","url":"https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","name":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation - 9Bio Therapeutics","isPartOf":{"@id":"https:\/\/9biotx.com\/#website"},"datePublished":"2025-05-14T05:13:00+00:00","dateModified":"2026-01-20T14:25:24+00:00","breadcrumb":{"@id":"https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/9biotx.com\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/9biotx.com\/"},{"@type":"ListItem","position":2,"name":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation"}]},{"@type":"WebSite","@id":"https:\/\/9biotx.com\/#website","url":"https:\/\/9biotx.com\/","name":"9Bio Th\u00e9rapeutiques","description":"Engineering Biological Possibilities","publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/9biotx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/9biotx.com\/#organization","name":"9Bio Th\u00e9rapeutiques","url":"https:\/\/9biotx.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/","url":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","contentUrl":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","width":200,"height":80,"caption":"9Bio Therapeutics"},"image":{"@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/9bio\/"]},{"@type":"Person","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8","name":"Henrique de Carvalho","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","caption":"Henrique de Carvalho"},"sameAs":["https:\/\/9bio.ca"]}]}},"taxonomy_info":{"category":[{"value":1,"label":"News"}]},"featured_image_src_large":false,"author_info":{"display_name":"Henrique de Carvalho","author_link":"https:\/\/9biotx.com\/fr\/news\/author\/decarvalho\/"},"comment_info":1,"category_info":[{"term_id":1,"name":"News","slug":"news","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"9Bio News","parent":0,"count":7,"filter":"raw","cat_ID":1,"category_count":7,"category_description":"9Bio News","cat_name":"News","category_nicename":"news","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/comments?post=1983"}],"version-history":[{"count":5,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1983\/revisions"}],"predecessor-version":[{"id":1989,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1983\/revisions\/1989"}],"wp:attachment":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/media?parent=1983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/categories?post=1983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/tags?post=1983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}